LaCreta FP - Search Results

1

Age and gender effects on the pharmacokinetics of gatifloxacin.

LaCreta FP, Kollia GD, Duncan G, Behr D, Grasela DM. LaCreta FP, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):67S-75S. doi: 10.1592/phco.20.8.67s.35185. Pharmacotherapy. 2000. PMID: 10850523

2

Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.

Grasela DM, LaCreta FP, Kollia GD, Randall DM, Uderman HD. Grasela DM, et al. Among authors: lacreta fp. Pharmacotherapy. 2000 Mar;20(3):330-5. doi: 10.1592/phco.20.4.330.34878. Pharmacotherapy. 2000. PMID: 10730688 Clinical Trial.

3

A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.

Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, Grasela DM. Gajjar DA, et al. Among authors: lacreta fp. Pharmacotherapy. 2000 Jun;20(6 Pt 2):49S-58S. doi: 10.1592/phco.20.8.49s.35186. Pharmacotherapy. 2000. PMID: 10850521 Clinical Trial.

4

Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.

LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. LaCreta FP, et al. Pharmacotherapy. 2000 Jun;20(6 Pt 2):59S-66S. doi: 10.1592/phco.20.8.59s.35183. Pharmacotherapy. 2000. PMID: 10850522 Clinical Trial.

5

Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.

Gajjar DA, LaCreta FP, Kollia GD, Stolz RR, Berger S, Smith WB, Swingle M, Grasela DM. Gajjar DA, et al. Among authors: lacreta fp. Pharmacotherapy. 2000 Jun;20(6 Pt 2):76S-86S. doi: 10.1592/phco.20.8.76s.35182. Pharmacotherapy. 2000. PMID: 10850524 Clinical Trial.

6

Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.

Grasela DM, Christofalo B, Kollia GD, Duncan G, Noveck R, Manning JA Jr, LaCreta FP. Grasela DM, et al. Among authors: lacreta fp. Pharmacotherapy. 2000 Jun;20(6 Pt 2):87S-94S. doi: 10.1592/phco.20.8.87s.35187. Pharmacotherapy. 2000. PMID: 10850525

7

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.

Yan JH, Bifano M, Olsen S, Smith RA, Zhang D, Grasela DM, LaCreta F. Yan JH, et al. J Clin Pharmacol. 2006 Nov;46(11):1250-8. doi: 10.1177/0091270006293304. J Clin Pharmacol. 2006. PMID: 17050790 Clinical Trial.

8

Absence of a pharmacokinetic interaction between entecavir and adefovir.

Bifano M, Yan JH, Smith RA, Zhang D, Grasela DM, LaCreta F. Bifano M, et al. J Clin Pharmacol. 2007 Oct;47(10):1327-34. doi: 10.1177/0091270007304780. Epub 2007 Aug 3. J Clin Pharmacol. 2007. PMID: 17675455 Clinical Trial.

9

Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients.

Zhu M, Bifano M, Xu X, Wang Y, LaCreta F, Grasela D, Pfister M. Zhu M, et al. Antimicrob Agents Chemother. 2008 Aug;52(8):2836-41. doi: 10.1128/AAC.01366-07. Epub 2008 Apr 7. Antimicrob Agents Chemother. 2008. PMID: 18391039 Free PMC article. Clinical Trial.

10

Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.

Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Frost CE, et al. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0. Clin Pharmacokinet. 2015. PMID: 25573421 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters